Lung cancer: district active treatment rates affect survival

被引:45
作者
Cartman, ML
Hatfield, AC
Muers, MF
Peake, MD
Haward, RA
Forman, D
机构
[1] NYCRIS, Leeds, W Yorkshire, England
[2] Gen Infirm, Leeds LS1 3EX, W Yorkshire, England
[3] Pontefract Dist Gen Hosp, Pontefract, Wales
关键词
D O I
10.1136/jech.56.6.424
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Study objective: This study investigates variation in management and treatment of lung cancer patients and determines the impact of any variation in treatment on survival. Design: A retrospective study of population based data held by the Northern & Yorkshire Cancer Registry and Information Service (NYCRIS), comparing active treatment rates for lung cancer with by districts. Setting: The then 17 districts in Yorkshire and South Humber, England. Patients: 22 654 patients registered with lung cancer between 1986 and 1994 and followed up until end of 1996. Results: The overall rates of active treatment (surgery, radiotherapy, and chemotherapy) varied between districts from 37% to 56%. One year survival (with 95% CI) was significantly better in the districts with highest rates of active treatment 23% (22% to 24%) compared with 19% (17% to 20%) for those with lowest treatment rates. Non-small cell lung cancer patients (55%) in the districts with highest active treatment rates had an age adjusted relative risk of death during the follow up period, relative to risk of death in the districts with the lower treatment rates of 0.88 (0.83 to 0.92). Clinically diagnosed patients (34%) had an age adjusted RR of 0.92 (0.86 to 0,96). RR in small cell cancer (11%) was not significant. Conclusion: This study has shown wide variations in the rates of active treatment for lung cancer patients within districts across one large region of England. Active treatment was strongly associated with improved survival, especially in non-small cell lung cancer.
引用
收藏
页码:424 / 429
页数:6
相关论文
共 32 条
[21]  
*ONS, 2000, HLTH STAT Q, V6, P71
[22]   Breast, lung and colorectal cancer incidence and survival in South Thames Region, 1987-1992: the effect of social deprivation [J].
Pollock, AM ;
Vickers, N .
JOURNAL OF PUBLIC HEALTH MEDICINE, 1997, 19 (03) :288-294
[23]   A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC) [J].
Roszkowski, K ;
Pluzanska, A ;
Krzakowski, M ;
Smith, AP ;
Saigi, E ;
Aasebo, U ;
Parisi, A ;
Tran, NP ;
Olivares, R ;
Berille, J .
LUNG CANCER, 2000, 27 (03) :145-157
[24]  
SCHRIJVERS CTM, 1995, CANCER-AM CANCER SOC, V75, P2946, DOI 10.1002/1097-0142(19950615)75:12<2946::AID-CNCR2820751223>3.0.CO
[25]  
2-6
[26]   Beliefs among pulmonologists and thoracic surgeons in the therapeutic approach to non-small cell lung cancer [J].
Schroen, AT ;
Detterbeck, FC ;
Crawford, R ;
Rivera, MP ;
Socinski, MA .
CHEST, 2000, 118 (01) :129-137
[27]  
*SCOTT INT GUID NE, 1998, SIGN PUBL, V23
[28]   Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews [J].
Silvestri, G ;
Pritchard, R ;
Welch, HG .
BRITISH MEDICAL JOURNAL, 1998, 317 (7161) :771-775
[29]  
*SMAC, 1994, MAN LUNG CANC CURR C
[30]   TIME TRENDS IN THE OUTCOME OF LUNG-CANCER MANAGEMENT - A STUDY OF 9,090 CASES DIAGNOSED IN THE MERSEY REGION, 1974-86 [J].
WATKIN, SW ;
HAYHURST, GK ;
GREEN, JA .
BRITISH JOURNAL OF CANCER, 1990, 61 (04) :590-596